Portal de Periódicos da CAPES

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

2019; Elsevier BV; Volume: 30; Issue: 7 Linguagem: Inglês

10.1093/annonc/mdz123

1569-8041

Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo, Chun Xin, Min Hee Hong, Beung‐Chul Ahn, Y. Kim, Seong Jin Choi, Hong In Yoon, J.G. Lee, C.Y. Lee, Sung Yong Park, S.-H. Park, Byoung Chul Cho, Hyo Sup Shim, Eui‐Cheol Shin, H.R. Kim,

Pancreatic and Hepatic Oncology Research

Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However, emerging evidence show that PD-1/PD-L1 blockade can lead to hyperprogressive disease (HPD), a flair-up of tumor growth linked to dismal prognosis. This study aimed to evaluate the incidence of HPD and identify the determinants associated with HPD in patients with NSCLC treated with PD-1/PD-L1 blockade.